These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23285002)

  • 1. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients.
    Shields RK; Clancy CJ; Gillis LM; Kwak EJ; Silveira FP; Massih RC; Eschenauer GA; Potoski BA; Nguyen MH
    PLoS One; 2012; 7(12):e52349. PubMed ID: 23285002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
    Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
    Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients.
    Tsioutis C; Kritsotakis EI; Karageorgos SA; Stratakou S; Psarologakis C; Kokkini S; Gikas A
    Int J Antimicrob Agents; 2016 Nov; 48(5):492-497. PubMed ID: 27542315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acinetobacter baumannii infection in solid organ transplant recipients.
    Kitazono H; Rog D; Grim SA; Clark NM; Reid GE
    Clin Transplant; 2015 Mar; 29(3):227-32. PubMed ID: 25580999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors of multidrug-resistant, extensively drug-resistant and pandrug-resistant Acinetobacter baumannii ventilator-associated pneumonia in a Medical Intensive Care Unit of University Hospital in Thailand.
    Inchai J; Liwsrisakun C; Theerakittikul T; Chaiwarith R; Khositsakulchai W; Pothirat C
    J Infect Chemother; 2015 Aug; 21(8):570-4. PubMed ID: 26026660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolates: Is there any benefit of adding tigecycline to aerosolized colistimethate sodium?
    Jean SS; Hsieh TC; Lee WS; Hsueh PR; Hsu CW; Lam C
    Medicine (Baltimore); 2018 Sep; 97(39):e12278. PubMed ID: 30278498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis.
    Kengkla K; Kongpakwattana K; Saokaew S; Apisarnthanarak A; Chaiyakunapruk N
    J Antimicrob Chemother; 2018 Jan; 73(1):22-32. PubMed ID: 29069421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of mortality in patients with extensively drug-resistant Acinetobacter baumannii pneumonia receiving colistin therapy.
    Choi IS; Lee YJ; Wi YM; Kwan BS; Jung KH; Hong WP; Kim JM
    Int J Antimicrob Agents; 2016 Aug; 48(2):175-80. PubMed ID: 27423416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
    Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
    J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.
    Durante-Mangoni E; Signoriello G; Andini R; Mattei A; De Cristoforo M; Murino P; Bassetti M; Malacarne P; Petrosillo N; Galdieri N; Mocavero P; Corcione A; Viscoli C; Zarrilli R; Gallo C; Utili R
    Clin Infect Dis; 2013 Aug; 57(3):349-58. PubMed ID: 23616495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Distribution, Drug Resistance, and Clinical Characteristics of Acinetobacter baumannii Infections in Solid Organ Transplant Recipients.
    Nie XM; Huang PH; Ye QF; Wan QQ
    Transplant Proc; 2015 Dec; 47(10):2860-4. PubMed ID: 26707303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.
    Cheng A; Chuang YC; Sun HY; Sheng WH; Yang CJ; Liao CH; Hsueh PR; Yang JL; Shen NJ; Wang JT; Hung CC; Chen YC; Chang SC
    Crit Care Med; 2015 Jun; 43(6):1194-204. PubMed ID: 25793437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen.
    Shields RK; Kwak EJ; Potoski BA; Doi Y; Adams-Haduch JM; Silviera FP; Toyoda Y; Pilewski JM; Crespo M; Pasculle AW; Clancy CJ; Nguyen MH
    Diagn Microbiol Infect Dis; 2011 Jun; 70(2):246-52. PubMed ID: 21353436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia.
    Yilmaz GR; Guven T; Guner R; Kocak Tufan Z; Izdes S; Tasyaran MA; Acikgoz ZC
    J Infect Dev Ctries; 2015 May; 9(5):476-85. PubMed ID: 25989167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: a preliminary report.
    Nakwan N; Wannaro J; Thongmak T; Pornladnum P; Saksawad R; Nakwan N; Chokephaibulkit K
    Pediatr Pulmonol; 2011 Jan; 46(1):60-6. PubMed ID: 20812247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii.
    Kwon SH; Ahn HL; Han OY; La HO
    Biol Pharm Bull; 2014; 37(3):340-6. PubMed ID: 24583855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii.
    Dong X; Chen F; Zhang Y; Liu H; Liu Y; Ma L
    J Antibiot (Tokyo); 2014 Sep; 67(9):677-80. PubMed ID: 25095805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trend of extensively drug-resistant Acinetobacter baumannii and the remaining therapeutic options: a multicenter study in Tehran, Iran over a 3-year period.
    Jasemi S; Douraghi M; Adibhesami H; Zeraati H; Rahbar M; Boroumand MA; Aliramezani A; Ghourchian S; Mohammadzadeh M
    Lett Appl Microbiol; 2016 Dec; 63(6):466-472. PubMed ID: 27626896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis.
    Liu J; Shu Y; Zhu F; Feng B; Zhang Z; Liu L; Wang G
    J Glob Antimicrob Resist; 2021 Mar; 24():136-147. PubMed ID: 32889142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
    Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.